Literature DB >> 14761726

In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria.

Nicolas C Issa1, Mark S Rouse, Kerryl E Piper, Walter R Wilson, James M Steckelberg, Robin Patel.   

Abstract

The minimum inhibitory concentration and minimum bactericidal concentration of BAL9141 against 150 clinical isolates of gram-negative bacteria were determined and compared to those of cefepime and ceftriaxone. BAL9141 exhibited comparable activity to cefepime and ceftriaxone against Haemophilus influenzae, Klebsiella pneumoniae, and extended-spectrum beta-lactamase nonproducing Enterobacter cloacae, and comparable activity to cefepime against Pseudomonas aeruginosa.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14761726     DOI： 10.1016/j.diagmicrobio.2003.09.006

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  13 in total

1.  Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.

Authors:  Pierre Vaudaux; Asllan Gjinovci; Manuela Bento; Dongmei Li; Jacques Schrenzel; Daniel P Lew
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.

Authors:  Tatiana Bogdanovich; Catherine Clark; Lois Ednie; Gengrong Lin; Kathy Smith; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.

Authors:  Tatiana Bogdanovich; Lois M Ednie; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

4.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

Review 5.  Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

6.  In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2006-09-18       Impact factor: 5.191

7.  Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.

Authors:  Thomas P Lodise; Rienk Pypstra; James B Kahn; Bindu P Murthy; Hui C Kimko; Karen Bush; Gary J Noel; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

8.  In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.

Authors:  W A Craig; D R Andes
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

Review 9.  Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity.

Authors:  Bindu Murthy; Anne Schmitt-Hoffmann
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

10.  Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.

Authors:  Anne Marie Queenan; Wenchi Shang; Malgosia Kania; Malcolm G P Page; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2007-06-25       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.